Intercept Pharmaceuticals has nabbed the FDA's breakthrough therapy designation for obeticholic acid, a closely watched therapy in the pipeline for a blockbuster NASH indication.
Merck KGaA, in the process of paring down its pipeline, is walking away from a $625 million deal with Symphogen and handing back the company's lead asset, a targeted cancer treatment in midstage trials.
India's Biocon held a busy earnings call on Jan. 23 that highlighted extensive spending on research and keeping several deals rolling, though tight-lipped on a possible license to make Gilead's chronic hepatitis C products and said it will sell a 10% to 15% stake in its research services arm Syngene through an initial public offering.
Pfizer is well behind its rival titans in the race to cash in on a new class of cancer treatments. But instead of playing catch-up in skin cancer, the industry first immuno-oncology target, the drugmaker is skipping ahead to the next wave of malignancies.
Enanta Pharmaceuticals, perhaps best known as AbbVie's partner in hepatitis C, has blueprinted its next big solo step, joining the race to develop treatments for a pervasive liver disease with blockbuster potential.
Argos Therapeutics' HIV treatment failed to meet its main goal in a midstage trial, raising concerns about the company's platform technology and sending its shares spiraling downward.
AbbVie investigators delivered a fresh set up promising results for a key late-stage drug in the pipeline. In the first of two Phase III studies, the company reports that both doses of elagolix scored statistically significant results for chronic and painful cases of endometriosis among pre-menopausal women.
Isis Pharmaceuticals is shifting its cardiovascular pipeline into a new subsidiary, cutting the ribbon on Akcea Therapeutics and appointing former Genzyme executive Paula Soteropoulos to lead the way.
Battered by a string of clinical failures, Aveo Oncology is cutting the cord on its internal research operation, ditching two-thirds of its staff and shaking up the C suite.
Zafgen charted a third major victory for its in-development obesity drug, spurring weight loss for patients who have endured brain injuries and stoking hopes for success in Phase III.